Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitch Dowsett

Showing results (81-90 of 359) with videos related to

Pageof 36
Sort By:
Journal of Clinical Pathology|August 19, 2015
Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity studyAndrew Dodson, Lila Zabaglo, Belinda Yeo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating studyMitch Dowsett, Jack Cuzick, Chris Wale, et al.
Journal of the National Cancer Institute|February 22, 2007
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trialTrevor J Powles, Sue Ashley, Alwynne Tidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2010
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trialIvana Sestak, Wolfgang Distler, John F Forbes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancerGiles Davies, Janine Salter, Margaret Hills, et al.
The Journal of Steroid Biochemistry and Molecular Biology|July 6, 2005
Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistanceStephen R D Johnston, Lesley-Ann Martin, Julia Head, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancerElizabeth J Folkerd, J Michael Dixon, Lorna Renshaw, et al.
Journal of Pineal Research|January 31, 2006
Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levelsEva S Schernhammer, Candyce H Kroenke, Mitch Dowsett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancerJames M Rae, Meredith Regan, Brian Leyland-Jones, et al.
The American Journal of Clinical Nutrition|January 30, 2004
The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trialCharlotte Atkinson, Juliet E Compston, Nicholas E Day, et al.
Pageof 36

Showing results (81-90 of 359) with videos related to

Sort By:
Pageof 36
Journal of Clinical Pathology|August 19, 2015
Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity studyAndrew Dodson, Lila Zabaglo, Belinda Yeo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2005
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating studyMitch Dowsett, Jack Cuzick, Chris Wale, et al.
Journal of the National Cancer Institute|February 22, 2007
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trialTrevor J Powles, Sue Ashley, Alwynne Tidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2010
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trialIvana Sestak, Wolfgang Distler, John F Forbes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2003
Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancerGiles Davies, Janine Salter, Margaret Hills, et al.
The Journal of Steroid Biochemistry and Molecular Biology|July 6, 2005
Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistanceStephen R D Johnston, Lesley-Ann Martin, Julia Head, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancerElizabeth J Folkerd, J Michael Dixon, Lorna Renshaw, et al.
Journal of Pineal Research|January 31, 2006
Urinary 6-sulfatoxymelatonin levels and their correlations with lifestyle factors and steroid hormone levelsEva S Schernhammer, Candyce H Kroenke, Mitch Dowsett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancerJames M Rae, Meredith Regan, Brian Leyland-Jones, et al.
The American Journal of Clinical Nutrition|January 30, 2004
The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trialCharlotte Atkinson, Juliet E Compston, Nicholas E Day, et al.
Pageof 36